RCKT Rocket Pharmaceuticals Inc

$RCKT you do realize, management doesn't control the stock of the company right..... Its 95% institutionally owned, which means when the 1% decides they want it to run, they will make it run out of no where, no based on anything else. So you can be angry at everyone, but you are not yelling at the right plp. $RCKT is poised to run to $30-$50 and $90-$100 with BO, the science is there, the approvals are there, the lineup is there.... Only thing investors need is patience, why.... because the markets reward the patient, not the greedy who want everything NOW!, TODAY! Invest in the science and company. And learn to control the greed and ego.

$RCKT RCKT has $283 million in cash/cash equivalents and market cap is now 295 million. Interesting..

$RCKT is further clarifying the FDA-aligned pivotal Phase 2 trial and reports that the first three patients treated with the modified dose have so far experienced no TMA or capillary leak syndrome, while all six key Phase 1 patients showed LAMP2 expression and at least a 10% reduction in LV mass after approximately 12 months. Also particularly interesting: reported short interest is around 15 million shares, roughly 17% of the float, with about 11 days to cover. If the market starts to reprice the safety risk, that could add a meaningful short squeeze component.

$RCKT Blackrock inc. paid $3.86 per share that they bought september 2th, 2026 If they are not worried, why should you be ? ❤️❤️🫡❤️❤️

$RCKT 13 days left before RCKT make their conference to shareholders about Danon. I think that we are getting closer for a buyout. ❤️

$RCKT Rocket Pharmaceuticals’ Danon update strengthens the RP-A501 story. The first 3 patients on the revised 3.8×10¹³ GC/kg dose completed the initial safety period without TMA or capillary leak syndrome. FDA has aligned on a 12-patient pivotal study, with ≥7 patients required to achieve BOTH LAMP2 expression and ≥10% LVMI reduction at 12 months. Three patients already count, leaving only 9 to dose, with completion targeted for mid-2027. Earlier Phase 1 data continue to show durable biological and cardiac effects, while Rocket sees a $1B+ peak opportunity in the initial male indication alone. The Hercules facility is another major positive: $35M upfront within a potential $150M facility, alongside $283.7M in existing cash/investments. Rocket expects funding into Q3 2028, with additional financing potentially extending runway into 2029 — reducing near-term dilution risk while funding the pivotal program and potential BLA. ::

$RCKT total trash Rocket Pharma management is honestly trash. They should have pushed much harder for a BLA given the extensive clinical history with RP-A501, including years of functional and biomarker data and 6 patients already dosed in the pivotal trial before the hold. Add the lower-dose regimen specifically designed to address the safety issues, and there was a strong basis to argue for a more flexible regulatory path in such an ultra-rare disease. Instead, Rocket's painfully slow execution has left us needing 9 additional patients. Promising science, but absolutely terrible execution

$RCKT i traded this stock in the twenties (at a loss) not that long ago. Fuck happend here?

The market is still pricing $RCKT as if there’s a meaningful chance RP-A501 never succeeds, the company’s valuation is roughly around its cash level, which means the Danon program is effectively being assigned very little value. That’s why tonight could be explosive!! if Rocket shows that the new dose is both safe and still biologically active, the market may have to sharply raise the probability of success, and reprice the entire stock accordingly. Anyone?

$RCKT I think this is an interesting stock leading up to the 10/06/2026 meeting. Elaborating on the FDA news could be a nice catalyst. 🚀🍌🦍

$RCKT is one I’m watching closely here. They already have an FDA-approved gene therapy, but the bigger catalyst could be Danon disease.

$RCKT honestly, i hate this market. Trump and his cronies are propping it up, spreading lies and diverting attention from every negative indicator to keep the market from collapsing. Still, this one looks like a bargain to me.

$RCKT Blackrock inc. have $25,752,681 millions in Rocket Pharmaceuticals. Now, that is a lot of money to invest in a small biotech. They know what they are doing. They are not moving, no matter what the share price is. At the end of the race they know that they will have a winner. Blackrock is worth 176.49 billions. That is just one of the investors. 🥰

$RCKT There is a lot of misinformation about RCKT on this board. I don’t know whether this is intentional or simply due to a lack of knowledge about the company. Rather than replying to posts, here is a response: Let’s stop pretending everything is fine. RCKT has fallen roughly 23% since Sept 17 on heavy volume and is approaching its 52-week low. This is not simply “minor market adjustments.” The market is disappointed that the Oct 6 Danon update will not provide new efficacy data. Gaurav Shah said at Morgan Stanley that it is simply too early. RCKT has not sold a pipeline project. The $180M came from monetizing the Priority Review Voucher awarded after KRESLADI’s FDA approval. The buyer remains confidential. The real problem is the timeline: dosing is expected to finish around mid-2027, while pivotal 12-month efficacy data may not be available until 2028. At the current share price, a capital raise could be highly dilutive. These are real issues—not simply “minor market adjustments.”

$RCKT In an effort to alleviate all fear and apprehension of potential investors of RCKT stock, I spent the last 2 days telling people at my local grocery store about all of the wonderful things going on at this company. Although most customers simply walked away from me, I did get quite a few perplexing and quizzical stares, leading me to believe that they were seriously considering purchasing some shares.

$RCKT What in bloody tarnations wreaked holy havoc on this badly beleaguered stock today?

$RCKT Rocket Pharmaceuticals, Inc. (RCKT) has entered into a credit facility agreement with Hercules Capital, Inc. (HTGC) for up to $150 million, according to a company press release.

$RCKT - This is an unfortunate but expected price action. The dosing for the new 9 patients wont conclude until mid-late 2027 then the efficiency data from that is even longer - so you are looking at 2028. So the stock is doing what it should be doing ......

$RCKT an interesting tidbit I've seen is that the recalibrated danon dose is using the same commercial grade product they plan to move forward with. It's nice to see the trial getting closer to the eventual real world setup

$RCKT There was one slide on the RTW Biotech Opportunites Ltd's Results presentation this morning that gave a very prominent position to Rocket. The slide about how they create companies. I thought this was quite noticeable. Compared to the other companies they showed on the same slide which have generated huge value for them, Rocket looked rather good. I took it that despite the huge drop in Rocket's share price from recent years, they are becoming more proud of it: which I take as a sign that they can see value realisation coming.